Erasca Faces Class Action Lawsuit Over ERAS-0015 Disclosures

The lawsuit, Cheng v. Erasca, Inc., filed in the Southern District of California, claims top executives violated the Securities Exchange Act of 1934. According to the complaint, the company misrepresented the preclinical data for ERAS-0015, a pan-RAS molecular glue. Specifically, the suit alleges the firm used improper comparisons to competitors, risking patent infringement and trade secret misappropriation claims from Revolution Medicines, Inc.

Financial fallout followed the disclosure of these legal challenges on April 27, 2026, when Erasca stock dropped nearly 11%. Later that day, the company reported a patient death in its Phase I clinical trial for ERAS-0015 and clarified that its previous performance comparisons were not based on head-to-head trials. Following these revelations, the company’s share price declined by more than 48%. Robbins Geller Rudman & Dowd LLP is representing the class, urging investors with significant losses to contact attorneys Ken Dolitsky or Michael Albert to participate in the proceedings.